azacitidine and bryostatin 1

azacitidine has been researched along with bryostatin 1 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Horton, Y; Roddie, PH; Turner, ML1
Kalberer, CP; Langenkamp, U; Rohner, A; Siegler, U; Wodnar-Filipowicz, A1
Barat, C; Dental, C; Ouellet, M; Proust, A; Tremblay, MJ1

Other Studies

3 other study(ies) available for azacitidine and bryostatin 1

ArticleYear
Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1.
    Leukemia, 2002, Volume: 16, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Azacitidine; Bryostatins; CD40 Ligand; Cell Differentiation; Child; Cytokines; Dendritic Cells; Drug Resistance; Drug Synergism; Female; Granulocyte-Macrophage Colony-Stimulating Factor; HLA-D Antigens; Humans; Hydroxamic Acids; Immunophenotyping; In Situ Hybridization, Fluorescence; Interleukin-12; Interleukin-4; Karyotyping; Lactones; Leukemia, Myeloid; Lymphocyte Culture Test, Mixed; Macrolides; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2002
Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis.
    Leukemia research, 2007, Volume: 31, Issue:10

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bryostatins; Cell Differentiation; Cell Line, Tumor; Cholecalciferol; Cytotoxicity, Immunologic; Decitabine; Flow Cytometry; GPI-Linked Proteins; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Leukemia, Myeloid; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin; Up-Regulation

2007
HIV-1 Latency-Reversing Agents Prostratin and Bryostatin-1 Induce Blood-Brain Barrier Disruption/Inflammation and Modulate Leukocyte Adhesion/Transmigration.
    Journal of immunology (Baltimore, Md. : 1950), 2017, 02-01, Volume: 198, Issue:3

    Topics: Acetamides; Azacitidine; Azepines; Blood-Brain Barrier; Bryostatins; Cell Adhesion; Cell Adhesion Molecules; Cell Movement; Cells, Cultured; Chemokine CCL2; Cytokines; Decitabine; HIV-1; Humans; Inflammation; Intercellular Adhesion Molecule-1; Leukocytes; Phorbol Esters; Quinazolines; Receptors, Cell Surface; Virus Latency

2017